AB Science S.A., a pharmaceutical company, engages in the research, development, and commercialization of protein kinase inhibitors for use in human and veterinary medicines in the United States and Europe. Its lead compound includes Masitinib, a tyrosine kinase inhibitor that targets mast cells and selected kinases, including c-Kit, PDGR, and Lyn. The company focuses on therapies for the treatment of cancer, inflammatory diseases, and central nervous system diseases. It is also pursuing eight on-going phase III studies in human medicine in GIST, metastatic melanoma expressing JM mutation of c-Kit, multiple myeloma, mastocytosis, severe persistent asthma, rheumatoid arthritis, and progressive multiple sclerosis. The company markets its Masitinib under the Masivet brand name for the veterinary market in Europe. Its products are used by hospitals and specialist physicians. AB Science S.A. was founded in 2001 and is headquartered in Paris, France.
ab science sa (AB:Euronext Paris)
3, Avenue George V
Phone: 33 1 47 20 00 14
Fax: 33 1 47 20 24 11www.ab-science.com
|No competitor information is available for AB.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact AB SCIENCE SA, please visit www.ab-science.com. Company data is provided by Capital IQ. Please use this form to report any data issues.